Expert Opinion on Pharmacotherapy 5: Investigation and Management, CrossRef BeckerRichard C. An expert consensus document with focus on atrial fibrillation.
Subscribers log in here. Share on Social Media. Dodson, Jersey Chen, John A. Until more evidence becomes available, the use of ticagrelor or prasugrel in the context of double or triple therapy is not recommended as stated in the ESC consensus document.
One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: Supported in part by the Norwegian Council on Cardiovascular Disease. National Center for Biotechnology InformationU. All of the early antithrombotic therapies were associated with an increased bleeding risk, regardless of the INR level at admission.
CrossRef 63 Sharif M. Appendix The following centers and investigators all in Norway participated in this study: Nature Reviews Cardiology 7 A wonderful resource tool with great updates. Marc Cohen, Deepa Iyer. Ljosland; Regional Hospital of Trondheim — J.
CrossRef 37 Jonathan A. The evidence concerning the combination of NOACs and antiplatelet therapy is scarce.
At the end of the study, a total of patients had discontinued the assigned medication at some point during the study period of 80 months: Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. Van de Werf, L. Thrombin activity at the site of plaque rupture may result in delayed or incomplete reperfusion of occluded vessels and contributes to reocclusion.